most effective semaglutide dose (Ozempic) for Type 2 Diabetes Mellitus Semaglutide & Tirzepatide Dosing Guide:

Findings Could Extend Beyond People With HIV Although the research focused on people with HIV-associated lipohypertrophy, the investigators believe the findings could have broader implications

Lauren was really great

Theranostics 11 (7), 30523059

Rapid Risk Reduction Seen in First Months The study found that semaglutide was associated with a 38% reduced risk of major adverse cardiovascular events (MACE) within the first 3 months compared to placebo (36 vs 58, respectively) Within the first 6 months, semaglutide was associated with a 41% reduced risk of MACE compared to placebo (67 vs 113, respectively) Notably, at 3 and 6 months, most patients had not yet lost much weight and many were not yet on the full target dose of semaglutide 2.4 mg weekly